CDNA Stock Overview
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CareDx, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.17 |
| 52 Week High | US$12.93 |
| 52 Week Low | US$4.80 |
| Beta | 1.45 |
| 1 Month Change | -14.36% |
| 3 Month Change | -17.64% |
| 1 Year Change | 2.13% |
| 3 Year Change | -89.87% |
| 5 Year Change | -69.97% |
| Change since IPO | -18.30% |
Recent News & Updates
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02
Recent updates
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price
Jun 29Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)
May 16CareDx: Shaking Off First-Mover Disadvantage
Oct 18CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
Aug 08Shareholder Returns
| CDNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.1% | -2.5% | -3.2% |
| 1Y | 2.1% | -3.7% | 19.3% |
Return vs Industry: CDNA exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: CDNA underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDNA's share price has been volatile over the past 3 months.
Volatility Over Time: CDNA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 639 | John Hanna | caredx.com |
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
CareDx, Inc Fundamentals Summary
| CDNA fundamental statistics | |
|---|---|
| Market cap | US$423.03m |
| Earnings (TTM) | -US$190.28m |
| Revenue (TTM) | US$280.32m |
1.5x
P/S Ratio-2.2x
P/E RatioIs CDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDNA income statement (TTM) | |
|---|---|
| Revenue | US$280.32m |
| Cost of Revenue | US$102.00m |
| Gross Profit | US$178.33m |
| Other Expenses | US$368.61m |
| Earnings | -US$190.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.67 |
| Gross Margin | 63.61% |
| Net Profit Margin | -67.88% |
| Debt/Equity Ratio | 0% |
How did CDNA perform over the long term?
See historical performance and comparison